Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemosensitivity testing in ovarian cancer

B U Sevin1, J P Perras, H E Averette

  • 1Division of Gynecologic Oncology, University of Miami School of Medicine, FL 33136.

Cancer
|February 15, 1993
PubMed
Summary

A new in vitro assay measuring adenosine triphosphate improves ovarian cancer chemosensitivity testing. This method offers higher evaluability rates and personalized drug response profiles for better treatment selection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammasome-dependent IL-1β release depends upon membrane permeabilisation.

Cell death and differentiation·2016
Same author

Gestational trophoblastic disease in a fifty-one year old woman.

Oncology reports·2011
Same author

Advanced mucinous adenocarcinoma in pregnancy.

Oncology reports·2011
Same author

Hormonal modulation of radiation in uterine-cancer cell-lines.

International journal of oncology·2011
Same author

Use of lonidamine to potentiate the effect of cisplatin and carboplatin on platinum resistant human ovarian cancer cells.

International journal of oncology·2011
Same author

Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.

Gynecologic oncology·2001

Area of Science:

  • Oncology
  • Biochemistry
  • Pharmacology

Background:

  • Ovarian cancer treatment relies on surgery and chemotherapy, with drug selection based on clinical trial response rates, not individual sensitivity.
  • Current in vitro chemosensitivity assays for ovarian cancer have low evaluability rates due to poor tumor cell growth and harsh disaggregation methods.
  • Existing methods like the human tumor clonogenic assay show low plating efficiencies (0.001-0.1%) and evaluability (40-70%).

Purpose of the Study:

  • To develop and evaluate a novel in vitro chemosensitivity assay for ovarian cancer using intracellular adenosine triphosphate (ATP) levels.
  • To assess the sensitivity, specificity, and evaluability of the new ATP-based assay in fresh gynecologic tumor specimens.
  • To characterize individual drug-response patterns and tumor heterogeneity in ovarian cancer patients.

Related Experiment Videos

Main Methods:

  • A new in vitro assay was developed measuring intracellular adenosine triphosphate (ATP) to detect drug-induced tumor cell viability decrease.
  • The assay was validated on over 150 fresh gynecologic tumor specimens, including ovarian tumors.
  • Single drugs and drug combinations were tested at five concentrations (10-500% of peak plasma concentrations).

Main Results:

  • The novel ATP-based assay demonstrated high evaluability rates for ovarian tumors, exceeding 90%.
  • Preliminary data showed a sensitivity of 92% and a specificity of 100% for the assay.
  • Significant variability in drug response was observed among tumors, even those morphologically similar, highlighting tumor heterogeneity.

Conclusions:

  • The developed ATP-based in vitro assay significantly improves the evaluability of ovarian cancer chemosensitivity testing.
  • This assay provides a more reliable method for assessing individual patient drug responses, addressing limitations of previous assays.
  • Characterizing individual chemosensitivity profiles is crucial for optimizing ovarian cancer treatment and overcoming drug resistance.